5 Top Losers In Healthcare Sector (THOR, GTHX, CSU...)

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Synthorx Inc. (THOR)

Synthorx is a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders.

Lost 16.71% to close Wednesday's (Mar.6) trading at $15.38.

News: No news

Recent event:

On December 7, 2018, the Company's shares made their debut on the Nasdaq Global Select Market, at an offering price of $11.00 each.

2. G1 Therapeutics Inc. (GTHX)

G1 Therapeutics is a clinical-stage oncology company.

Lost 16.42% to close Wednesday's trading at $17.31.

News: No news

Clinical Trials & Near-term Catalysts:

-- Trilaciclib, under phase II trials in small cell lung cancer and metastatic triple-negative breast cancer.

Preliminary results from the trials were reported last year, and they showed meaningful benefit for the drug candidate across different indications, lines of therapy and chemotherapy regimens.

Additional trials with Trilaciclib are expected to be initiated in the second half of 2019.

-- Lerociclib is under a phase IIa expansion study in combination with Faslodex in ER+, HER2- breast cancer.

-- G1T48, under a phase I/IIa clinical trial as monotherapy for the treatment of ER+, HER2-breast cancer. Preliminary data from this trial is expected in 4Q19.

3. Capital Senior Living Corp. (CSU)

Lost 16.42% to close Wednesday's trading at $17.31.

CSU is an operator of senior housing communities.

News: No news

Recent events:

On February 28, the Company reported disappointing financial results for the fourth quarter and full year ended December 31, 2018.

Revenue in the fourth quarter of 2018, including all communities, was $115.1 million, a $1.9 million, or 1.6%, decrease from the fourth quarter of 2017. Revenue for full-year 2018 was $460.0 million, a $7.0 million, or 1.5%, decrease from the full year 2017.

4. TRACON Pharmaceuticals Inc. (TCON)

TRACON is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer.

Lost 12.31% to close Wednesday's trading at $1.21.

News: No news

Near-term Catalysts:

-- A pivotal phase III trial of TRC105 in patients with angiosarcoma, dubbed TAPPAS, is underway. The announcement of the results of the interim analysis to determine the final sample size of the pivotal TAPPAS trial is expected in April. -- Presentation of preclinical data by Leiden University researchers on the activity of TRC105 in combination with checkpoint inhibitors at the American Association for Cancer Research (AACR) annual meeting in Philadelphia, PA is expected in March. -- Presentation of expanded cohort data by the National Cancer Institute from the Phase 1 trial of TRC102 and Temodar in patients with colorectal, lung and ovarian cancer at the AACR annual meeting in Philadelphia, PA is expected in April. -- Presentation of TRC253 Phase 1 data in patients with metastatic castrate-resistant prostate cancer is expected in the first half of 2019. -- Announcement of first in human dosing of TJ4309 is expected in the first half of 2019.

5. Daxor Corporation (DXR)

Daxor manufactures and markets FDA-cleared BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit.

Lost 12.02% to close Wednesday's trading at $15.88.

News: No news

Recent event:

On March 4, the Company announced that its kit sales rose over 18% year-on-year in the cardiology segment, driven by increasing awareness of the value of blood volume analysis to improve heart failure outcomes through reduced mortality and readmission.